Endogenous HER2-specific CD4+ T cells and antibodies have been detected in patients with HER2-expressing cancers [22,23], and in clinical trials, HER2-specific CD4+ and CD8+ T-cell responses could be induced by peptide vaccination [24,25]. Here, ERBB2 is linked to cancer.